Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25754451 | 0.87 | NOS3 (0.34) | NOS3NOS1NOS2 | |
| SCHEMBL25754453 | 0.84 | HTT (0.46) | CYP1A2CYP3A4CYP2C19HTT | |
| SCHEMBL25754456 | 0.82 | NOS3 (0.33) | NOS3NOS1NOS2CYP1A2CYP3A4 | |
| SCHEMBL25754448 | 0.78 | TLR2 (0.42) | NOS3NOS1NOS2CYP3A4HTT | |
| SCHEMBL25754461 | 0.73 | ALDH1A1 (0.36) | CYP1A2HTT | |
| SCHEMBL24633956 | 0.72 | NOS3 (0.58) | HSD17B10NOS3NOS1NOS2TDP1 | |
| SCHEMBL11413953 | 0.72 | NOS3 (0.58) | HSD17B10NOS3NOS1NOS2TDP1 | |
| SCHEMBL26763535 | 0.72 | HSD17B10 (0.46) | HSD17B10NOS3NOS1NOS2TDP1 | |
| SCHEMBL1287187 | 0.72 | NOS3 (0.58) | HSD17B10NOS3NOS1NOS2TDP1 | |
| SCHEMBL7359495 | 0.69 | HSD17B10 (0.43) | HSD17B10NOS3NOS1NOS2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | HSD17B10 2815/4885NOS3 4364/4885NOS1 4701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.